Tactile Systems (TCMD) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue grew 5% year-over-year to $73.1 million, with lymphedema up 4–4.4% and airway clearance up 10%.

• Net income was $5.2 million, down from $22.3 million in Q3 2023 due to prior-year tax benefits and earn-out adjustments.

• Gross margin expanded by 410 basis points year-over-year to 75.0%, driven by lower material and warranty costs.

• Adjusted EBITDA increased to $10.7 million, marking the 10th consecutive quarter of improvement.

• A $30 million share repurchase program was authorized, to be funded with cash on hand.

Financial highlights

• Q3 total revenue: $73.1 million (+5% year-over-year); nine months: $207.4 million (+5%).

• Gross margin: 75% (vs. 70.9% prior year); non-GAAP gross margin: 75.4% (vs. 71.4%).

• Net income: $5.2 million ($0.21 per diluted share), down from $22.3 million ($0.94 per share) due to prior year tax adjustment.

• Adjusted EBITDA: $10.7 million (14.6% of sales), up from $7.7 million (11.1%).

• Operating cash flow for nine months: $24.3 million (up from $17.5 million year-over-year).

Outlook and guidance

• 2024 revenue guidance revised to $292–$295 million (6–8% growth year-over-year).

• Adjusted EBITDA guidance raised to $35–$37 million for 2024.

• GAAP gross margin expected at ~74%; operating expenses to increase low double digits.

• Management expects cash, equivalents, and operating cash flow to be sufficient for at least the next twelve months.

• Minimal Q4 impact expected from new Nimble product or Medicare policy change.